Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AstraZeneca plc (AZN) vs Roundhill Magnificent Seven ETF (MAGS) Price & Performance

AstraZeneca plcTrade
Roundhill Magnificent Seven ETFTrade

Price performance (Past 24H)

Key statistics

AstraZeneca plc vs Roundhill Magnificent Seven ETF — how do they compare? AstraZeneca plc trades at $158.5 (market cap $248.14B), while Roundhill Magnificent Seven ETF trades at $67.78. The key difference: AstraZeneca plc pays a 2.01% dividend while Roundhill Magnificent Seven ETF pays none, and Roundhill Magnificent Seven ETF is trading nearer its 52-week high, AstraZeneca plc nearer its low. Which is the better fit depends on your goals.

AZNMAGS
Market Cap
$248.14B
Sector
HealthSector/Thematic
52-Week High
$209.48$70.94
52-Week Low
$147.06$55.39
Enterprise Value
$275.41B
Dividend Yield
2.01%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AstraZeneca plc

AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.

The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.

Roundhill Magnificent Seven ETF

MAGS trades at $67.95, down 1.58% today, with technical indicators showing a bullish moving average trend but overbought RSI levels. The ETF holds equal-weighted exposure to the Magnificent Seven tech stocks, which have underperformed the broader market this year amid shifting investor focus toward semiconductors and AI infrastructure. Recent news highlights concerns over aggressive AI capital spending pressuring dividends and buybacks.

The outlook remains cautious as AI profit realization lags expectations, though hyperscaler valuations are compressed. Key risks include concentration in tech, high expectations, and macroeconomic sensitivity. Analyst sentiment is mixed, with some seeing long-term AI potential but near-term headwinds from earnings pressure and market rotation.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AstraZeneca plc

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.

Read more on AZN

About Roundhill Magnificent Seven ETF

MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.

Read more on MAGS